Originally published on CVS Health Company Newsroom

WOONSOCKET, R.I., SEPTEMBER 23, 2026 /3BL/ — CVS Health® (NYSE: CVS) recently announced the launch of its nationwide “Wear Your HeART” Bandage Art Contest, inviting people across the United States to submit original artwork inspired by the importance of protecting personal, family and community health.

The contest offers artists, students, families and community groups an opportunity to turn their creativity into a source of inspiration for millions of Americans. Four Grand Prize winners will have their designs featured on limited-edition CVS brand adhesive bandages that will be used in CVS Pharmacy® locations nationwide for immunizations beginning in Fall 2027. Winners will be recognized on related promotional materials and receive $5,000.

“Protection can look different for everyone, whether it’s getting vaccinated, caring for a loved one, or taking small steps to stay healthy,” said Erin Condon, Chief Marketing Officer, Pharmacy and Consumer Wellness, CVS Health. “Through this contest, we’re inviting people to share their unique perspectives on what it means to protect their health and their communities.”

Contest Details

The “Wear Your HeART” Bandage Art Contest is open to legal residents of the United States. Adults age 18 and older may enter on their own behalf, while entries from those under age 18 must be submitted by a parent, legal guardian or another adult age 18 or older.

Participants may enter individually or as part of a group. Each person or group is limited to one entry.

Artwork submissions should creatively reflect a design inspired by what protecting their health means to them and designs must include the CVS heart as part of the artwork.

Entries will be evaluated based on several criteria, including:

  • Story and impact: Clear, compelling and authentic storytelling and a demonstrated understanding of the “Protect Your Health” theme
  • Creativity and expression: Original and unique artwork that adheres to contest theme
  • Execution and quality: Completion of all submission requirements and demonstrated effort and attention to detail
  • Brand alignment: Thoughtful incorporation of the CVS Health heart within the design

Judging Process

Following the submission period, entries will undergo an initial review by a panel of judges. Finalists may advance to additional evaluation phases before final selections are made.

A panel of CVS Health judges will select four Grand Prize winners in accordance with the official judging criteria. Selected winners will be notified directly and announced publicly in January 2027.

How to Enter

Eligible participants can submit their design and required information at CVSWearYourHeART.com between September 15, 2026 and November 30, 2026. Required submission information includes contact details, city and state of residence, and, for entrants under age 18, information and consent from a parent or legal guardian.

Official contest rules, eligibility requirements and complete submission instructions are available at CVSWearYourHeART.com.

NO PURCHASE NECESSARY. Void where prohibited. The CVS® Wear Your HeART Contest is sponsored by CVS Pharmacy, Inc. Open to legal residents of the 50 U.S. and DC. Individuals under the age of 18 must have their parent or legal guardian enter on their behalf. Begins at 9:00 a.m. ET on 9/15/26 & ends 11:59 p.m. ET on 11/30/26. For complete eligibility details and official rules, visit CVSWearYourHeART.com.

###

About CVS Health

CVS Health is a leading health solutions company simplifying health care one person, one family and one community at a time. As of June 30, 2026, the Company had approximately 9,000 retail pharmacy locations, more than 1,000 walk-in and primary care medical clinics and a leading pharmacy benefits manager with approximately 87 million plan members. The Company also serves an estimated 37 million people through a broad range of health insurance products and related services. The Company’s integrated model uses personalized, technology driven services to connect people to simply better health, increasing access to quality care, delivering better outcomes, and lowering overall costs.

Media contact 

Amy Thibault
401-318-2865
Amy.Thibault@CVSHealth.com

 

Company announcement no 47/2026 Danske Bank
Bernstorffsgade 40
DK-1577 København V
Tel. + 45 45 14 14 00

23 September 2026

Page 1 of 1

Danske Bank A/S – major shareholder announcement from BlackRock, Inc.

In accordance with section 30 of the Danish Capital Markets Act, we disclose that BlackRock, Inc. on 19 May, 26 May and 21 July 2026 notified Danske Bank that BlackRock, Inc., pursuant to section 38(2) of the Danish Capital Markets Act, holds the following shares and voting rights of Danske Bank A/S:

  • As of 19 May 2026, BlackRock, Inc held 5% of the shares and voting rights of Danske Bank A/S, and via financial instruments, pursuant to section 39(2)(2) of the Danish Capital Markets Act, held 0.15% of the shares and voting rights of Danske Bank A/S, in total 5.15% of the shares and voting rights of Danske Bank A/S.
  • As of 26 May 2026, BlackRock, Inc held 4.99% of the shares and voting rights of Danske Bank A/S, and via financial instruments, pursuant to section 39(2)(2) of the Danish Capital Markets Act, held 0.16% of the shares and voting rights of Danske Bank A/S, in total 5.15% of the shares and voting rights of Danske Bank A/S.
  • As of 21 July 2026, BlackRock, Inc held 5% of the shares and voting rights of Danske Bank A/S, and via financial instruments, pursuant to section 39(2)(2) of the Danish Capital Markets Act, held 0.27% of the shares and voting rights of Danske Bank A/S, in total 5.27% of the shares and voting rights of Danske Bank A/S.

As of 21 July 2026, BlackRock, Inc. held a total of 43,034,599 shares and voting rights in Danske Bank A/S, corresponding to 5.27% of the total share capital and voting rights.

Danske Bank A/S

Contact: Head of Investor Relations, Claus Ingar Jensen, tel. +45 25 42 43 70

Attachment

New York, NY, Sept. 23, 2026 (GLOBE NEWSWIRE) — ARC Group Securities Acquisition I (the “Company” (Nasdaq: FJDIU) (the “Company”) today announced that, commencing on or about September 24, 2026, holders of the units sold in the Company’s initial public offering may elect to separately trade the Company’s Class A ordinary shares, warrants and rights included in the units.

The Class A ordinary shares, warrants and rights that are separated will trade on The Nasdaq Stock Market LLC (“Nasdaq”) under the symbols “FJDI”, “FJDIW”, and “FJDIR” respectively. Those units not separated will continue to trade on Nasdaq under the symbol “FJDIU”. Holders of units will need to have their brokers contact Efficiency, Inc., the Company’s transfer agent, in order to separate the units into Class A ordinary shares, warrants and rights.

The public offering was made only by means of a prospectus. Copies of the prospectus relating to the offering may be obtained from ARC Group Securities LLC at 398 S. Mill Avenue, Suite 306, Tempe, AZ 85281, or by email at operations@arc-securities.com. A registration statement on Form S-1 (File No. 333-291302) relating to the securities was declared effective by the U.S. Securities and Exchange Commission on August 3, 2026. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

ARC Group Securities Acquisition I

ARC Group Securities Acquisition I is a blank check company, also commonly referred to as a special purpose acquisition company, or SPAC, formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities. While the Company may pursue an acquisition opportunity in any business, industry, sector or geographical location, the Company intends to focus on companies on industries where the Company’s management teams’ and affiliates’ expertise will provide the Company with a competitive advantage, including technology, healthcare and logistics industries. 

Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements,” including with respect to the Company’s search for an initial business combination. No assurance can be given that the offering discussed above will be completed on the terms described, or at all, or that the net proceeds of the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and preliminary prospectus for the initial public offering filed with the SEC. Copies are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contact:

ARC Group Securities Acquisition I
398 S. Mill Avenue, Suite 306
Tempe, Arizona 85281
Attn: Ian Hanna
Chief Executive Officer & Chairman
(928) 625-0928

Phase III advances development of a modular, reusable, swarm based, precision-strike capability designed for U.S. Special Operations Forces, powered by XTEND’s operating system, XOS.

TAMPA, Fla., Sept. 23, 2026 (GLOBE NEWSWIRE) — XTEND AI Robotics, Inc. (NYSE: XTND), a leader in software systems and Physical AI, today announced that it has been awarded Phase III of the U.S. Special Operations Command (USSOCOM) Modular Kinetic Lethal Drone (MKLD) program, advancing the Company’s continued work in precision-strike unmanned systems for U.S. Special Operations Forces. The award is separate from, and follows, XTEND’s recent selection as a top performer in the Close-Quarters Battle segment of Gauntlet II under the U.S. Department of War’s Drone Dominance Program.

The MKLD solution brings together XTEND’s Striker, Scorpio 500 and Scorpio 1000 platforms with a common Ground Control Station and XTEND’s XOS operating system. The program is designed to provide small tactical units with modular, recoverable and reusable precision-strike capabilities across indoor, confined-space, urban and outdoor operational environments.

“Phase III is an important milestone in our continued work with the U.S. Special Operations community,” said Aviv Shapira, CEO and Co-Founder of XTEND. “Our focus is on giving Warfighters adaptable robotic capabilities that extend their reach and effectiveness while shifting risk from the operator to unmanned systems.”

Phase III builds on previous USSOCOM investment, development, testing and operational feedback and will further mature the MKLD capability.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the capabilities of XOS and the MKLD solution, the anticipated development and maturation of the MKLD capability under Phase III and XTEND’s financial prospects, including that according to the Drone Dominance Program the 10 companies selected for Gauntlet II are finalists for prototype contracts and awards are not guaranteed. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially, including the timing and size of orders from government and defense customers, the availability of government funding, the risk that the MKLD program does not advance beyond Phase III or result in production orders, geopolitical and economic conditions in the United States and the other regions in which XTEND operates, and the other risks described under “Risk Factors” in the registration statement on Form S-4 filed with the SEC in connection with the business combination and in XTEND’s other filings with the SEC, available at www.sec.gov. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this press release. XTEND does not undertake any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by applicable law.

About XTEND AI Robotics, Inc.

XTEND AI Robotics, Inc. (the “Company”) operates under two distinct business strategies. Through its wholly owned subsidiary XTEND Reality Expansion Ltd. (“XTEND”), the Company develops and sells software and advanced robotic hardware solutions for high-threat, complex operational environments where human exposure carries significant risk. Powered by its proprietary XTEND Operating System (“XOS”), these solutions are designed to provide autonomy at the edge. Through its wholly owned subsidiary JFB Construction Holdings (“JFB”), the Company operates a commercial and residential real estate construction and development strategy, delivering services including retail corporate buildouts, multifamily developments and luxury residential homes. The Company was formed through the combination of XTEND and JFB, uniting two complementary businesses to pursue shared technology and market opportunities, including applying XTEND’s AI-enabled drone technology to jobsite security, land surveying, building inspections and monitoring on JFB’s real estate projects, and leveraging JFB’s construction expertise to help reduce the cost of XTEND’s U.S. manufacturing expansion.

Contacts

XTEND Media Contact:
Headline Media
Sarah Small
929-255-1449
sarah@headline.media

XTEND Investor Relations:
MZ North America
Shannon Devine
203-741-8811
XTND@mzgroup.us

NEW YORK–(BUSINESS WIRE)–Madison Square Garden Entertainment Corp. (“MSG Entertainment”) (NYSE: MSGE) today announced details around the new elements in the 2026 Christmas Spectacular Starring the Radio City Rockettes® to ‘ring’ in the next century of the iconic dance company, including the brand-new Radio City Rockettes® performance number and new immersive technology that will expand how audiences experience America’s most beloved holiday show. Entitled “Ring” and performed to the Christmas

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.